Dr. A.M. Nisar Syed, MD
Claim this profileStudies Ductal Carcinoma In Situ
Studies Breast cancer
1 reported clinical trial
1 drug studied
More about A.M. Nisar Syed, MD
Clinical Trial Related13 years of experience running clinical trials · Led 1 trial as a Principal Investigator · 0 Active Clinical TrialsTreatments A.M. Nisar Syed, MD has experience with
- Xoft® Axxent® EBx® IORT System®
Breakdown of trials A.M. Nisar Syed, MD has run
Ductal Carcinoma In Situ
Breast cancer
Ductal Carcinoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does A.M. Nisar Syed, MD specialize in?
A.M. Nisar Syed, MD focuses on Ductal Carcinoma In Situ and Breast cancer. In particular, much of their work with Ductal Carcinoma In Situ has involved treating patients, or patients who are undergoing treatment.
Is A.M. Nisar Syed, MD currently recruiting for clinical trials?
No, A.M. Nisar Syed, MD is not currently recruiting for any clinical trials. This may change in the future, so check back later.
Are there any treatments that A.M. Nisar Syed, MD has studied deeply?
Yes, A.M. Nisar Syed, MD has studied treatments such as Xoft® Axxent® eBx® IORT System®.
What is the best way to schedule an appointment with A.M. Nisar Syed, MD?
Apply for one of the trials that A.M. Nisar Syed, MD is conducting.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.